title: Increased neurite outgrowth of cultured rat dorsal root ganglion cells following transection or inhibition of axonal transport of the sciatic nerve.
abstract: Dissociated dorsal root ganglion cells (DRGs), taken from rats 2 weeks after sciatic nerve transection, have an increase in the percentage of cells with neurites compared to DRGs taken from normal animals. This study examines the possible factors that may contribute to the nerve injury-induced increase in neuritogenesis. Topical application of the local anaesthetic, bupivicaine, either to the nerve trunk prior to transection or to the proximal nerve stump for 2 weeks had no effect on the increased neurite outgrowth induced by nerve transection. Neurite outgrowth was also not influenced by administration of either nerve growth factor (NGF) via the femoral artery into normal rats or anti-NGF antiserum to the proximal nerve stump. Inhibition of axonal transport by topical application of vinblastine, however, induced a significant increase in neurite outgrowth compared to untreated controls. In addition, vinblastine-treated animals also develop hyperalgesia to mechanical stimulation and transganglionic labelling of sensory neurons with choleragenoid-horseradish peroxidase shows that the area of termination of myelinated sensory neurons in the spinal cord expands into lamina II. The results suggest that nerve injury-induced increase in neurite outgrowth is not dependent on NGF nor nerve impulses generated at the site of injury and supports the view that the absence of an inhibitory factor(s), that in normal animals may regulate neuronal outgrowth.
authors.affiliation: Department of Anaesthesia and Pain Management, University of Sydney, N.S. W., 2065, Australia.
authors.forename: D M
authors.initials: DM
authors.lastname: White
authors.forename: K
authors.initials: K
authors.lastname: Mansfield
authors.forename: K
authors.initials: K
authors.lastname: Kelleher
mesh_terms: D000779:Anesthetics, Local / Q000494:pharmacology; D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology; D001370:Axonal Transport / Q000187:drug effects / Q000502:physiology*; D001369:Axons / Q000502:physiology; D002045:Bupivacaine / Q000494:pharmacology; D002478:Cells, Cultured / Q000187:drug effects / Q000502:physiology / Q000648:ultrastructure; D005727:Ganglia, Spinal / Q000166:cytology*; D006735:Horseradish Peroxidase; D008297:Male; D009413:Nerve Fibers, Myelinated / Q000502:physiology; D009414:Nerve Growth Factors / Q000494:pharmacology; D016501:Neurites / Q000502:physiology*; D009475:Neurons, Afferent / Q000187:drug effects / Q000502:physiology* / Q000648:ultrastructure; D009619:Nociceptors / Q000187:drug effects / Q000502:physiology; D051381:Rats; D017208:Rats, Wistar; D012584:Sciatic Nerve / Q000166:cytology*; D014747:Vinblastine / Q000494:pharmacology
chemical_list: D000779:Anesthetics, Local; D000972:Antineoplastic Agents, Phytogenic; D009414:Nerve Growth Factors; D014747:Vinblastine; D006735:Horseradish Peroxidase; D002045:Bupivacaine